Filtered By:
Cancer: Lung Cancer
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
CONCLUSION: Atezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile.PMID:37603816 | DOI:10.1200/JCO.22.02561
Source: Clinical Lung Cancer - August 21, 2023 Category: Cancer & Oncology Authors: Ernest Nadal Delvys Rodr íguez-Abreu Marta Sim ó Bartomeu Massut í Oscar Juan Gerardo Huidobro Rafael L ópez Javier De Castro Anna Estival Joaqu ín Mosquera Ivana Sullivan Enriqueta Felip Ana Blasco Maria Guirado Eva Pereira Noelia Vilari ño Valent Source Type: research
Dexamethasone induces cancer mitigation and irreversible senescence in lung cancer cells via damaging cortical actin and sustained hyperphosphorylation of pRb
Steroids. 2023 Jun 30:109269. doi: 10.1016/j.steroids.2023.109269. Online ahead of print.ABSTRACTActivation of the glucocorticoid receptors by its cognate ligand, dexamethasone (DEX) is commonly used as an adjuvant treatment in solid tumors. However, its direct effect on cancerous phenotype is not fully understood. We explored the effect and molecular mechanisms of DEX action in lung cancer. In in vitro experiments, DEX treatment causes decrease in migration, invasion and colony formation ability of A549 cells even at lower doses. DEX also decreased adhesion of A549 cells by reducing the formation of cortical actin. Treatm...
Source: Cell Research - July 2, 2023 Category: Cytology Authors: Swati Srivastava Shumaila Siddiqui Samradhi Singh Sangita Chowdhury Vishal Upadhyay Arppita Sethi Arun Kumar Trivedi Source Type: research
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
CONCLUSION: Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-line NSCLC when available.PMID:37196429 | DOI:10.1200/JCO.22.02546
Source: Clinical Lung Cancer - May 17, 2023 Category: Cancer & Oncology Authors: Nasser Hanna Frances A Shepherd Frank V Fossella Jose R Pereira Filippo De Marinis Joachim von Pawel Ulrich Gatzemeier Thomas Chang Yao Tsao Miklos Pless Thomas Muller Hong-Liang Lim Christopher Desch Klara Szondy Radj Gervais None Shaharyar Christian Man Source Type: research
Dexamethasone activates c-Jun NH2-terminal kinase (JNK) which interacts with GR and protects it from ubiquitin-mediated degradation in NSCLC cells
Biochem Biophys Res Commun. 2023 Jan 26;650:1-8. doi: 10.1016/j.bbrc.2023.01.079. Online ahead of print.ABSTRACTDexamethasone-mediated pharmacological activation of the glucocorticoid receptor (GR) is widely used in the treatment regimen of hematological malignancies and solid cancers. However, DEX sensitivity towards patients primarily depends on the endogenous protein levels of GR. We observed that DEX treatment leads to an increase in GR protein levels despite inhibition of neo-protein synthesis in non-small cell lung cancer (NSCLC) cells. Mechanistically, DEX-stimulation concomitantly increased the JNK phosphorylation ...
Source: Biochemical and Biophysical Research communications - February 10, 2023 Category: Biochemistry Authors: Swati Srivastava Shumaila Siddiqui Sangita Chowdhury Arun Kumar Trivedi Source Type: research
MPN-092 Paraneoplastic Eosinophilia: An Unusual Initial Presentation of Metastatic Pancreatic Adenocarcinoma
We report the case of a 58-year-old female patient, a previously healthy heavy smoker who presented with worsening abdominal pain and dyspnea. Laboratory tests revealed hypereosinophilia with an absolute eosinophilic count (AEC) of 65,000/mm3, thrombocytosis (platelets=890,000/mm3), and disturbed liver function tests. Chest-abdomen-pelvis CT scan showed a huge necrotic tumor in the tail of the pancreas associated with multiple regional and retroperitoneal lymph nodes, liver metastases, and multiple bilateral lung nodules with lymphangitic carcinomatosis. We performed the following laboratory tests to exclude different etio...
Source: Clinical Lung Cancer - September 27, 2022 Category: Cancer & Oncology Authors: Tarek Badra Samer Nehme Omaya Baydoun Georges El Hachem Source Type: research
Non-secretory multiple myeloma expressed as multiple extramedullary plasmacytoma with an endobronchial lesion mimicking metastatic cancer: A case report
CONCLUSION: We present a rare case of non-secretory MM with multiple extramedullary plasmacytoma with an endobronchial lesion.PMID:36158506 | PMC:PMC9372843 | DOI:10.12998/wjcc.v10.i22.7899
Source: Clinical Lung Cancer - September 26, 2022 Category: Cancer & Oncology Authors: Seul Bi Lee Chi Young Park Hee Jeong Lee Ran Hong Woo Shin Kim Sang-Gon Park Source Type: research
A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer
CONCLUSIONS: The dose of 12 mg/m2/q2Wk was declared the recommended phase II dose/schedule. At this dose/schedule, CT900 exhibited an acceptable side effect profile with clinical benefit in patients with high/medium α‑FR expression and warrants further investigation.PMID:35984704 | DOI:10.1158/1078-0432.CCR-22-1268
Source: Clinical Lung Cancer - August 19, 2022 Category: Cancer & Oncology Authors: Susana Banerjee Vasiliki Michalarea Joo Ern Ang Alvaro Ingles Garces Andrea Biondo Ionut-Gabriel Funingana Martin Little Ruth Ruddle Florence Raynaud Ruth Riisnaes Bora Gurel Sue Chua Nina Tunariu Joanna C Porter Toby Prout Mona Parmar Anna Zachariou Alis Source Type: research
Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study
CONCLUSION: Prophylactic administration of low-dose dexamethasone for 5 days from the day after pemetrexed administration resulted in a milder incidence and severity of rash. These findings may provide a standard preventative strategy for pemetrexed-induced rashes. (Trial identifier: UMIN000025666).PMID:35325241 | DOI:10.1093/oncolo/oyab077
Source: The Oncologist - March 24, 2022 Category: Cancer & Oncology Authors: Takumi Sakurada Hiroshi Nokihara Tadashi Koga Yoshito Zamami Mitsuhiro Goda Kenta Yagi Hirofumi Hamano Fuka Aizawa Hirokazu Ogino Seidai Sato Yasushi Kirino Hisatsugu Goto Yasuhiko Nishioka Keisuke Ishizawa Source Type: research
Effect of pretreatment with dexamethasone on the efficacy and immune-related adverse events of immunotherapy in first-line treatment for advanced non-small cell lung cancer: a network meta-analysis of randomized control trials
CONCLUSION: The combination treatment of I+C+D is the most effective approach for the first-line treatment of NSCLC patients treated with I+C, I, or C.PMID:35106186 | PMC:PMC8784760
Source: Clinical Lung Cancer - February 2, 2022 Category: Cancer & Oncology Authors: Yanwei Li Feng He Shuang Liu Yu Zhang Ling Li Bin Wang Lan Lan Zhanyu Pan Source Type: research
